Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo…
Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers Company shares further detail on the differentiators of IK-930, a TEAD-paralog…